New Findings Presented at 2019 ASCO Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data demonstrating the potential for its Afirma ® Xpression Atlas (XA) genomic test to guide targeted treatment selection for patients
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 29, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at two upcoming investor conferences: The William Blair 39 th Annual Growth Stock Conference in Chicago
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 23, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data demonstrating the Afirma® Xpression Atlas test’s ability to detect gene alterations that may be targeted by new treatments for medullary thyroid cancer – a rare, but aggressive
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2019-- Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, today announced new data demonstrating that its next-generation Percepta ® Genomic Sequencing Classifier (GSC) provides expanded lung cancer risk information that can
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Sangeeta Bhorade , M.D., medical director of pulmonology. In this role, Dr. Bhorade will lead medical affairs for Veracyte’s
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the UBS Global Healthcare Conference in New York City on
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 7, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,325,000 shares of common stock, including 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2019-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $23.25 per share.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2019-- Veracyte, Inc. (Nasdaq: VCYT) (“the Company”) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by Veracyte .
Grew Revenue by 47% to $29.5 Million Grew Genomic Test Volume by 33% to 9,162 Tests Company Raises 2019 Annual Revenue Guidance Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 30, 2019-- Veracyte, Inc.
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
